Olanib 150 mg (Olaparib) Medicine Services

administrations

by iebpharma il y a 2 mois 55 Views comments

0
0

For more information, consult a healthcare professional or refer to the medication guide provided with Olanib 150 mg.

Olanib 150 mg is a targeted cancer therapy containing Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor. It is primarily used to treat certain types of ovarian, breast, prostate, and pancreatic cancers that have specific genetic mutations, such as BRCA1 and BRCA2. Olanib works by preventing cancer cells from repairing their damaged DNA, leading to cell death and slowing the progression of the disease.

Medical Uses and Indications

Olanib 150 mg is prescribed for the treatment of:

  1. Ovarian Cancer – Used in patients with advanced ovarian cancer who have a BRCA mutation and have previously received chemotherapy.
  2. Breast Cancer – Approved for HER2-negative metastatic breast cancer in patients with a BRCA mutation.
  3. Prostate Cancer – Indicated for metastatic castration-resistant prostate cancer (mCRPC) in patients with homologous recombination repair (HRR) mutations.
  4. Pancreatic Cancer – Used as a maintenance therapy for metastatic pancreatic cancer in patients with a germline BRCA mutation.

Mechanism of Action

Olaparib, the active ingredient in Olanib 150 mg (Olaparib), inhibits the enzyme PARP, which plays a crucial role in repairing damaged DNA in cells. Cancer cells with BRCA mutations rely on PARP to survive and replicate. By blocking PARP activity, Olanib prevents the repair of DNA damage, causing cancer cells to die while sparing normal cells.

Dosage and Administration

  • The standard recommended dose is 300 mg per day, taken as two 150 mg tablets, twice daily.
  • It should be taken orally with or without food.
  • Dose adjustments may be required based on individual tolerance, kidney function, and side effects.
  • Patients should not crush, chew, or split the tablets.

Side Effects and Precautions

While Olanib 150 mg is an effective treatment, it may cause some side effects, including:

  • Common Side Effects: Fatigue, nausea, vomiting, diarrhea, anemia, decreased appetite, dizziness, and abdominal pain.
  • Serious Side Effects: Myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), pneumonitis, and severe bone marrow suppression.
  • Precautions:
    • Avoid use in pregnancy due to potential harm to the fetus.
    • Regular blood tests are required to monitor blood cell counts.
    • Inform the doctor about any pre-existing conditions, especially kidney or liver disease.

Drug Interactions

Olanib 150 mg may interact with other medications, including:

  • Strong CYP3A Inhibitors (e.g., ketoconazole, ritonavir) – May increase Olaparib levels in the blood, requiring dose reduction.
  • Strong CYP3A Inducers (e.g., rifampin, phenytoin) – May decrease the effectiveness of Olaparib by lowering drug levels.
  • Warfarin and Other Blood Thinners – Increased risk of bleeding.

Monitoring and Follow-Up

Patients taking Olanib 150 mg require regular monitoring:

  1. Blood Tests: To check hemoglobin levels, white blood cell count, and liver/kidney function.
  2. Radiologic Assessments: To evaluate treatment response and cancer progression.
  3. Physical Examinations: To assess side effects and adjust treatment accordingly.

Storage and Handling

  • Store at room temperature (20°C - 25°C) away from moisture and heat.
  • Keep out of reach of children.
  • Dispose of expired or unused medication according to local regulations.

Conclusion

Olanib 150 mg (Olaparib) is a powerful treatment option for patients with BRCA-mutated cancers. With its targeted mechanism, it improves survival rates and quality of life in eligible patients. However, it requires careful monitoring for side effects and potential interactions. Patients should follow their doctor's guidance closely to maximize the benefits of this medication while minimizing risks.

Comments